<DOC>
	<DOCNO>NCT00514943</DOCNO>
	<brief_summary>The primary objective study explore efficacy BIBW 2992 compare cetuximab ( Erbitux ) patient metastatic recurrent head neck cancer failure platinum-containing therapy . In addition , trial aim clarify influence EGFR genotype tumor response treatment regimen .</brief_summary>
	<brief_title>BIBW 2992 ( Afatinib ) Head &amp; Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion criterion : 1 . Metastatic ( stage IVc ) recurrent HNSCC 2 . Histologically cytologically confirm diagnosis squamous cell head neck . Patients welldifferentiated ( keratinize ) nasopharyngeal carcinoma patient squamous cell carcinoma metastatic neck unknown head neck primary eligible . 3 . Patients must document progressive disease ( PD ) follow receipt prior platinumbased therapy ( either neoadjuvant , adjuvant , concomitant radiotherapy , recurrent/ metastatic disease ) . 4 . Patients must measurable disease define RECIST criterion . 5 . Patients must recover therapyrelated toxicity previous chemo , immuno , radiotherapy CTC small equal Grade 1 . 6 . Patients must recover previous surgery . 7 . Life expectancy least three ( 3 ) month . 8 . Eastern Cooperative Oncology Group ( ECOG , R010787 ) performance score 0 1 . 9 . Patients must eighteen ( 18 ) year age old . 10 . Willingness ability give write informed consent consistent ICHGCP guideline . Exclusion criterion : 1 . Progressive disease within 3 month completion curative intent treatment localized/locoregionally advanced disease . 2 . Prior use EGFR erbB2 inhibitor recurrent/metastatic disease setting ( treatment cetuximab ( ErbituxÂ® ) EGFR inhibitor radiotherapy chemoradiotherapy permissible ) . 3 . More 2 chemotherapeutic regimen give recurrent/metastatic disease . 4 . Treatment investigational drug , anticancertherapy ( e.g. , chemotherapy , immunotherapy , radiotherapy ) , concomitantly therapy study and/or last four week , prior first treatment trial drug 5. eliminate per Amendment # 1 6 . Patients history malignancy ( except appropriately treat superficial basal cell skin cancer surgically cure cervical cancer situ ) unless free disease least 3 year . 7 . Patients history decompensated heart failure . 8 . Cardiac leave ventricular function rest ejection fraction &lt; 50 % le institutional low limit normal MUGA echocardiogram . 9 . Active infectious disease . 10 . Gastrointestinal disorder may interfere absorption study drug chronic diarrhea . 11 . Serious illness , concomitant nononcological disease mental problem consider investigator incompatible protocol . 12 . Use alcohol drug incompatible patient participation study investigator 's opinion . 13 . Patients unable comply protocol . 14 . Patients active/symptomatic brain metastasis . Patients history treat brain metastasis must stable normal cerebral MRI scan screening least three month postradiation surgery . 15 . Absolute neutrophile count ( ANC ) less 1000/mm3 . 16 . Platelet count less 75,000/mm3 . 17 . Bilirubin great 1.5 mg/dl/ Higher bilirubin value acceptable patient know Gilbert 's disease , approval PI sponsor necessary . 18 . Asparate amino transferase ( AST ) alanine amino transferase ( ALT ) great 3 time upper limit normal . 19 . Serum creatinine great 1.5 X upper limit normal institution . 20 . Patients sexually active unwilling use medically acceptable method contraception . 21 . Pregnancy breastfeed . 22 . Patients know preexist interstitial lung disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>